Oncology Clinical Trials in Dallas, TX

As of July 2026, 339 paid clinical trials are recruiting for Oncology in Dallas, Texas. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

339 clinical trials for Oncology

·Clear filters·↓ Download CSV

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Daratumumab

67 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

35 locations incl. Birmingham

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting

Apply to this trial

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for Mesothelioma

25 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05245500·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

for Pancreatic Cancer

28 locations incl. Fort Smith

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07409272·Phase 3·Recruiting

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

51 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting

Apply to this trial

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

for Prostate Cancer

27 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT06780670·Phase 2, Phase 3·Recruiting

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

32 locations incl. Irvine

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting

Apply to this trial

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

for H3 K27M

67 locations incl. Phoenix

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: All ages

Code: NCT05580562·Phase 3·Recruiting

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

33 locations incl. Irvine

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting

Apply to this trial

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

for Brain Tumor, Recurrent

54 locations incl. Phoenix

Sponsor: GT Medical Technologies, Inc.

Sex: All·Age: All ages

Code: NCT04427384·Recruiting

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

28 locations incl. Los Angeles

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

26 locations incl. Phoenix

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

29 locations incl. La Jolla

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting

Apply to this trial

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

for Bladder Carcinoma

33 locations incl. Birmingham

Sponsor: Guardant Health, Inc.

Sex: All·Age: 18+

Code: NCT05059444·Recruiting

Apply to this trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for Prostate Cancer

27 locations incl. Birmingham

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male·Age: 18+

Code: NCT06056830·Phase 3·Recruiting

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

35 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting

Apply to this trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

for Multiple Myeloma

Drug: Talquetamab

49 locations incl. Clovis

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06208150·Phase 3·Recruiting

Apply to this trial

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

for Cancer Harboring BRAF Alterations

30 locations incl. Beverly Hills

Sponsor: Fore Biotherapeutics

Sex: All·Age: 10+

Code: NCT05503797·Phase 2·Recruiting

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

32 locations incl. Birmingham

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

41 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

38 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

26 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

49 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting

Apply to this trial

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

for Neoplasms

30 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 1 - 39

Code: NCT05999994·Phase 2·Recruiting

Apply to this trial

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

for Carcinoma, Non-Small-Cell Lung

25 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05208762·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

for Solid Tumors

Drug: INCB161734

69 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07522073·Phase 3·Recruiting

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

89 locations incl. Chandler

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT06767514·Phase 3·Recruiting

Apply to this trial

Pan Tumor Rollover Study

for Cancer

59 locations incl. Huntsville

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT03899155·Phase 2·Recruiting

Apply to this trial

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

for Prostate Cancer

50 locations incl. Anchorage

Sponsor: Astellas Pharma Global Development, Inc.

Sex: Male·Age: 18+

Code: NCT02960022·Phase 2·Recruiting

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

67 locations incl. Birmingham

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774·Recruiting

Apply to this trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

for Advanced Solid Tumors

28 locations incl. Tucson

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT05914116·Phase 1, Phase 2·Recruiting

Apply to this trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

for Breast Cancer

Drug: Palazestrant

47 locations incl. Tucson

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06016738·Phase 3·Recruiting

Apply to this trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

27 locations incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2·Recruiting

Apply to this trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for Breast Cancer

17 locations incl. Prescott

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06695845·Phase 2·Recruiting

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

18 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

Drug: Giredestrant

20 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting

Apply to this trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

for Solid Tumors

Drug: Adagrasib

17 locations incl. Phoenix

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT07415031·Phase 2·Recruiting

Apply to this trial

Conditions in Oncology (Dallas, TX)

Solid tumor· 70 Non-small cell lung cancer (NSCLC)· 49 Breast cancer· 42 Cancer (any)· 28 Prostate cancer· 24 Colorectal cancer· 23 Pancreatic cancer· 22 Bladder cancer· 21 Gastric cancer· 19 Ovarian cancer· 17 Endometrial cancer· 17 Acute myeloid leukemia (AML)· 16 Esophageal cancer· 14 Kidney cancer· 14 Multiple myeloma· 13 Non-Hodgkin lymphoma· 13 Hematologic malignancy· 13 Head and neck cancer· 13 Metastatic breast cancer· 11 Neuroblastoma· 10 Triple-negative breast cancer· 9 Liver cancer· 9 Melanoma· 9 Biliary tract cancer· 7 Cervical cancer· 7 Chronic lymphocytic leukemia (CLL)· 7 Lung cancer· 6 Gastroesophageal junction cancer· 6 Glioma· 6 Leukemia (other)· 6 Myelodysplastic syndromes (MDS)· 6 Diffuse large B-cell lymphoma (DLBCL)· 6 HER2-negative breast cancer· 5 Small cell lung cancer· 5 Fallopian tube cancer· 5 Glioblastoma· 5 Follicular lymphoma· 5 Skin cancer· 5 Osteosarcoma· 5 HER2-positive breast cancer· 4 Metastatic prostate cancer· 4 Mantle cell lymphoma· 3 Small lymphocytic lymphoma· 3 Ewing sarcoma· 3 Mesothelioma· 3 Neuroendocrine tumors· 3 Metastatic colorectal cancer· 2 Chronic myelomonocytic leukemia· 2 Acute lymphoblastic leukemia· 2 Myelofibrosis· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Sarcoma· 2 Rhabdomyosarcoma· 2 Rectal cancer· 1 Uterine cancer· 1 Brain cancer· 1 Brain metastases· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Thyroid cancer· 1